Sparrow Pharmaceuticals is focused on developing innovative therapies that target the regulation of intracellular steroids, particularly cortisol, to address unmet medical needs in endocrinology and rheumatology. The company is advancing its proprietary HSD-1 inhibitor, clofutriben (SPI-62), which aims to treat endocrine disorders such as endogenous Cushing’s syndrome and autonomous cortisol secretion (ACS). By inhibiting HSD-1, Sparrow seeks to significantly reduce the levels of active cortisol in key tissues, thereby mitigating the adverse effects associated with excess cortisol production. This approach is particularly relevant for patients who currently rely on surgical interventions or existing therapies that carry serious side effects.

In addition to clofutriben, Sparrow is developing SPI-47, a combination therapy that pairs clofutriben with prednisolone, a glucocorticoid medication. This novel combination is designed to provide the therapeutic benefits of steroid treatments while minimizing their associated toxicities, particularly for conditions like polymyalgia rheumatica (PMR). By focusing on the intracellular regulation of steroids, Sparrow Pharmaceuticals aims to revolutionize the treatment landscape for patients suffering from steroid-related disorders, offering safer and more effective alternatives to traditional steroid therapies.

United States

Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.

Sparrow Pharmaceuticals

Company Details